Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANIP NASDAQ:MLTX NASDAQ:NTLA NASDAQ:OCUL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIPANI Pharmaceuticals$90.78-0.9%$90.11$52.50▼$99.50$1.99B0.58326,166 shs264,285 shsMLTXMoonLake Immunotherapeutics$9.38+3.1%$46.52$5.95▼$62.75$584.50M1.110.10 million shs7.70 million shsNTLAIntellia Therapeutics$25.46+4.0%$13.71$5.90▼$26.99$2.63B2.377.47 million shs9.91 million shsOCULOcular Therapeutix$11.94+0.3%$12.28$5.78▼$13.85$2.07B1.453.43 million shs4.07 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIPANI Pharmaceuticals-0.03%+1.63%-3.73%+38.65%+61.38%MLTXMoonLake Immunotherapeutics-1.94%+28.90%-85.11%-81.38%-81.75%NTLAIntellia Therapeutics+19.72%+30.44%+106.67%+101.23%+36.78%OCULOcular Therapeutix+3.39%+7.88%-6.29%+7.49%+27.79%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIPANI Pharmaceuticals$90.78-0.9%$90.11$52.50▼$99.50$1.99B0.58326,166 shs264,285 shsMLTXMoonLake Immunotherapeutics$9.38+3.1%$46.52$5.95▼$62.75$584.50M1.110.10 million shs7.70 million shsNTLAIntellia Therapeutics$25.46+4.0%$13.71$5.90▼$26.99$2.63B2.377.47 million shs9.91 million shsOCULOcular Therapeutix$11.94+0.3%$12.28$5.78▼$13.85$2.07B1.453.43 million shs4.07 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIPANI Pharmaceuticals-0.03%+1.63%-3.73%+38.65%+61.38%MLTXMoonLake Immunotherapeutics-1.94%+28.90%-85.11%-81.38%-81.75%NTLAIntellia Therapeutics+19.72%+30.44%+106.67%+101.23%+36.78%OCULOcular Therapeutix+3.39%+7.88%-6.29%+7.49%+27.79%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIPANI Pharmaceuticals 2.90Moderate Buy$99.149.21% UpsideMLTXMoonLake Immunotherapeutics 2.07Hold$36.00283.80% UpsideNTLAIntellia Therapeutics 2.52Moderate Buy$27.959.78% UpsideOCULOcular Therapeutix 2.75Moderate Buy$22.6389.49% UpsideCurrent Analyst Ratings BreakdownLatest MLTX, NTLA, OCUL, and ANIP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/9/2025ANIPANI PharmaceuticalsTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$77.00 ➝ $90.0010/8/2025OCULOcular TherapeutixHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $19.0010/8/2025ANIPANI PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)10/8/2025MLTXMoonLake ImmunotherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025NTLAIntellia TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025OCULOcular TherapeutixWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/7/2025MLTXMoonLake ImmunotherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$25.0010/6/2025NTLAIntellia TherapeuticsCitizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$33.0010/6/2025NTLAIntellia TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeMarket Perform ➝ Market Outperform$33.0010/3/2025OCULOcular TherapeutixPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$21.00 ➝ $31.0010/3/2025OCULOcular TherapeutixRobert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$17.00 ➝ $24.00(Data available from 10/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIPANI Pharmaceuticals$614.38M3.21$7.53 per share12.06$19.11 per share4.75MLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/A$7.09 per shareN/ANTLAIntellia Therapeutics$57.88M47.22N/AN/A$8.56 per share2.97OCULOcular Therapeutix$56.66M36.66N/AN/A$2.01 per share5.94Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIPANI Pharmaceuticals-$18.52M-$0.77N/A21.56N/A-1.37%25.03%8.00%11/14/2025 (Estimated)MLTXMoonLake Immunotherapeutics-$118.94M-$2.78N/AN/AN/AN/A-40.98%-35.81%11/6/2025 (Estimated)NTLAIntellia Therapeutics-$519.02M-$4.69N/AN/AN/A-908.48%-57.48%-45.04%11/6/2025 (Estimated)OCULOcular Therapeutix-$193.51M-$1.28N/AN/AN/A-382.51%-71.92%-49.36%11/13/2025 (Estimated)Latest MLTX, NTLA, OCUL, and ANIP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025MLTXMoonLake Immunotherapeutics-$0.89N/AN/AN/AN/AN/A11/6/2025Q3 2025NTLAIntellia Therapeutics-$1.00N/AN/AN/AN/AN/A9/8/2025Q2 2025ANIPANI PharmaceuticalsN/A$1.80N/AN/AN/A$211.37 million8/8/2025Q2 2025ANIPANI Pharmaceuticals$1.42$1.80+$0.38$0.36$187.18 million$211.37 million8/7/2025Q2 2025NTLAIntellia Therapeutics-$1.03-$0.99+$0.04-$0.98$12.26 million$14.25 million8/5/2025Q2 2025MLTXMoonLake Immunotherapeutics-$0.73-$0.87-$0.14-$0.87N/AN/A8/5/2025Q2 2025OCULOcular Therapeutix-$0.35-$0.39-$0.04-$0.39$13.12 million$13.46 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANIPANI PharmaceuticalsN/AN/AN/AN/AN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/AN/ANTLAIntellia TherapeuticsN/AN/AN/AN/AN/AOCULOcular TherapeutixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIPANI Pharmaceuticals1.392.541.96MLTXMoonLake Immunotherapeutics0.2116.6516.65NTLAIntellia TherapeuticsN/A5.195.19OCULOcular Therapeutix0.2310.1010.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIPANI Pharmaceuticals76.05%MLTXMoonLake Immunotherapeutics93.85%NTLAIntellia Therapeutics88.77%OCULOcular Therapeutix59.21%Insider OwnershipCompanyInsider OwnershipANIPANI Pharmaceuticals11.10%MLTXMoonLake Immunotherapeutics12.02%NTLAIntellia Therapeutics3.10%OCULOcular Therapeutix2.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANIPANI Pharmaceuticals60021.70 million19.29 millionOptionableMLTXMoonLake Immunotherapeutics264.23 million56.51 millionOptionableNTLAIntellia Therapeutics600107.35 million104.02 millionOptionableOCULOcular Therapeutix230174.00 million169.99 millionOptionableMLTX, NTLA, OCUL, and ANIP HeadlinesRecent News About These CompaniesOcular Therapeutix price target raised to $19 from $15 at H.C. WainwrightOctober 8 at 11:07 PM | msn.comHC Wainwright & Co. Maintains Ocular Therapeutix (OCUL) Buy RecommendationOctober 8 at 11:07 PM | msn.comPiper Sandler Lifts PT on Ocular Therapeutix (OCUL) to $31 From $21October 8 at 3:18 AM | finance.yahoo.comOcular Therapeutix™ to Participate in Upcoming Scientific ConferencesOctober 7 at 7:00 AM | globenewswire.comInsider Selling: Ocular Therapeutix (NASDAQ:OCUL) Insider Sells 9,653 Shares of StockOctober 7 at 4:34 AM | insidertrades.comOcular Therapeutix (NASDAQ:OCUL) Insider Sells $106,472.59 in StockOctober 6 at 6:40 PM | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Insider Jeffrey Heier Sells 10,502 SharesOctober 6 at 6:40 PM | marketbeat.comBaird Maintains Ocular Therapeutix (OCUL) Outperform RecommendationOctober 5, 2025 | msn.comEquities Analysts Set Expectations for OCUL FY2025 EarningsOctober 5, 2025 | americanbankingnews.comPiper Sandler Maintains Ocular Therapeutix (OCUL) Overweight RecommendationOctober 4, 2025 | msn.comLooking at the Changing Narrative for Ocular Therapeutix After Recent Analyst UpdatesOctober 4, 2025 | finance.yahoo.comOcular Therapeutix (NASDAQ:OCUL) Stock Rating Upgraded by Zacks ResearchOctober 4, 2025 | marketbeat.comBrokerages Set Ocular Therapeutix, Inc. (NASDAQ:OCUL) Price Target at $17.83October 4, 2025 | americanbankingnews.comOcular Therapeutix price target raised to $31 from $21 at Piper SandlerOctober 3, 2025 | msn.comOcular Therapeutix price target raised to $24 from $17 at BairdOctober 3, 2025 | msn.comWilliam Blair Has Positive Outlook of OCUL FY2025 EarningsOctober 3, 2025 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Earns "Buy" Rating from Chardan CapitalOctober 3, 2025 | americanbankingnews.comNeedham & Company LLC Issues Positive Forecast for Ocular Therapeutix (NASDAQ:OCUL) Stock PriceOctober 3, 2025 | americanbankingnews.comOcular Therapeutix's (OCUL) "Buy" Rating Reaffirmed at Chardan CapitalOctober 2, 2025 | marketbeat.comNeedham Maintains Ocular Therapeutix (OCUL) Buy RecommendationOctober 2, 2025 | msn.comOcular Therapeutix (OCUL) Falls Hard on $475-Million Share SaleOctober 2, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMLTX, NTLA, OCUL, and ANIP Company DescriptionsANI Pharmaceuticals NASDAQ:ANIP$90.78 -0.87 (-0.95%) Closing price 04:00 PM EasternExtended Trading$93.50 +2.72 (+3.00%) As of 06:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.MoonLake Immunotherapeutics NASDAQ:MLTX$9.38 +0.28 (+3.08%) Closing price 04:00 PM EasternExtended Trading$9.43 +0.05 (+0.53%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.Intellia Therapeutics NASDAQ:NTLA$25.46 +0.99 (+4.05%) Closing price 04:00 PM EasternExtended Trading$25.74 +0.28 (+1.10%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Ocular Therapeutix NASDAQ:OCUL$11.94 +0.03 (+0.25%) Closing price 04:00 PM EasternExtended Trading$12.28 +0.34 (+2.81%) As of 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally AI Meets Nuclear: Palantir’s Role in Energy Expansion Buy the Dip? Zillow’s Profit Comeback Meets Market Pressure Adobe Launches Premiere Pro on iPhone, Upside Ahead? Rocket Lab: A Space Giant Hitting New Highs—Time to Chase? After AI Hyperscaler Deal, Is Aehr Test Systems Stock on Sale? Why Archer Aviation Stock Is Soaring—And What Comes Next Lithium Americas: Why This 31% Rally Is More Than Just a Headline Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
